This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ishibashi, H. Articles by Sasano, H. Search for Related Content PubMed PubMed Citation Articles by Ishibashi, H. Articles by Sasano, H.

Progesterone Receptor in Non–Small Cell Lung Cancer—A Potent Prognostic Factor and Possible Target for Endocrine Therapy

Departments of ¹ Pathology and ² Molecular Medical Technology, Tohoku University School of Medicine, Sendai, Japan; ³ Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan; and ⁴ Department of Surgery, Sendai Kousei Hospital, Sendai, Japan

Requests for reprints: Takashi Suzuki, Department of Pathology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. Phone: 81-22-717-8050; Fax: 81-22-717-8051; E-mail: t-suzuki{at}patholo2.med.tohoku.ac.jp (Takashi Suzuki).

A possible involvement of gender-dependent factors has been postulated in development of human non–small-cell lung cancers (NSCLC), but its details remain unclear. In this study, we examined biological significance of progesterone receptor in NSCLCs. Progesterone receptor immunoreactivity was detected in 106 of 228 NSCLCs (46.5%). Progesterone receptor–positive NSCLC was frequently detected in female and adenocarcinoma, and was inversely associated with tumor-node-metastasis stage and histologic differentiation. Progesterone receptor status was also associated with better clinical outcome of the patients, and a multivariate analysis revealed progesterone receptor status as an independent prognostic factor. Progesterone-synthesizing enzymes were detected in NSCLCs, and tissue concentration of progesterone was higher in these cases (n = 42). Immunoblotting analyses showed the presence of progesterone receptor in three NSCLC cell lines (A549, LCSC#2, and 1-87), but not in RERF-LC-OK or PC3. Transcriptional activities of progesterone receptor were increased by progesterone in these three progesterone receptor–positive NSCLC cells by luciferase assays. Cell proliferation was inhibited by progesterone in these progesterone receptor–positive NSCLC cells in a dose-dependent manner, which was inhibited by progesterone receptor blocker. Proliferation of these tumor cells injected into nude mice was also dose-dependently inhibited by progesterone, with a concomitant increase of p21 and p27 and a decrease of cyclin A, cyclin E, and Ki67. Results of our present study suggested that progesterone receptor was a potent prognostic factor in NSCLCs and progesterone inhibited growth of progesterone receptor–positive NSCLC cells. Therefore, progesterone therapy may be clinically effective in suppressing development of progesterone receptor–positive NSCLC patients.

This article has been cited by other articles:

				H. Niikawa, T. Suzuki, Y. Miki, S. Suzuki, S. Nagasaki, J. Akahira, S. Honma, D. B. Evans, S.-i. Hayashi, T. Kondo, et al. Intratumoral Estrogens and Estrogen Receptors in Human Non-Small Cell Lung Carcinoma Clin. Cancer Res., July 15, 2008; 14(14): 4417 - 4426. [Abstract] [Full Text] [PDF]

				C. Rodriguez, H. Spencer Feigelson, A. Deka, A. V. Patel, E. J. Jacobs, M. J. Thun, and E. E. Calle Postmenopausal Hormone Therapy and Lung Cancer Risk in the Cancer Prevention Study II Nutrition Cohort Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 655 - 660. [Abstract] [Full Text] [PDF]

				T. J. Grifone, H. M. Haupt, V. Podolski, and J. J. Brooks Immunohistochemical Expression of Estrogen Receptors in Chondrosarcomas and Enchondromas International Journal of Surgical Pathology, January 1, 2008; 16(1): 31 - 37. [Abstract] [PDF]

				T Yoshimura, T Sumida, S Liu, A Onishi, S Shintani, P-Y Desprez, and H Hamakawa Growth inhibition of human salivary gland tumor cells by introduction of progesterone (Pg) receptor and Pg treatment Endocr. Relat. Cancer, December 1, 2007; 14(4): 1107 - 1116. [Abstract] [Full Text] [PDF]

				R. Shao, E. Egecioglu, B. Weijdegard, K. Ljungstrom, C. Ling, J. Fernandez-Rodriguez, and H. Billig Developmental and hormonal regulation of progesterone receptor A-form expression in female mouse lung in vivo: interaction with glucocorticoid receptors. J. Endocrinol., September 1, 2006; 190(3): 857 - 870. [Abstract] [Full Text] [PDF]

				J. M. Siegfried Hormone Replacement Therapy and Decreased Lung Cancer Survival J. Clin. Oncol., January 1, 2006; 24(1): 9 - 10. [Full Text] [PDF]